Organovo Partners With Autodesk Research to Develop 3D Bioprinting Software

 Organovo Partners With Autodesk Research to Develop 3D Bioprinting Software

PR Newswire

SAN DIEGO, Dec. 18, 2012

SAN DIEGO, Dec. 18, 2012 /PRNewswire/ --Organovo Holdings, Inc. (OTCQX: ONVO)
("Organovo"), a creator and manufacturer of functional, three-dimensional
human tissues for medical research and therapeutic applications, is working
together with researchers at Autodesk, Inc., the leader in cloud-based design
and engineering software, to create the first 3D design software for

The software, which will be used to control Organovo's NovoGen MMX bioprinter,
will represent a major step forward in usability and functionality for
designing three-dimensional human tissues, and has the potential to open up
bioprinting to a broader group of users.

"Autodesk is an excellent partner for Organovo in developing new software for
3D bioprinters," said Keith Murphy, Chairman and Chief Executive Officer at
Organovo. "This relationship will lead to advances in bioprinting, including
both greater flexibility and throughput internally, and the potential
long-term ability for customers to design their own 3D tissues for production
by Organovo."

"Bioprinting has the potential to change the world," said Jeff Kowalski,
Senior Vice President and Chief Technology Officer at Autodesk. "It's a blend
of engineering, biology and 3D printing, which makes it a natural for
Autodesk. I think working with Organovo to explore and evolve this emerging
field will yield some fascinating and radical advances in medical research."

Organovo's 3D bioprinting technology is used to create living human tissues
that are three-dimensional, architecturally correct, and made entirely of
living human cells. The resulting structures can function like native human
tissues, and represent an opportunity for advancement in medical research,
drug discovery and development, and in the future, surgical therapies and

The Autodesk Research group is dedicated to innovation and discovery ranging
from methods to help users learn powerful digital prototyping tools to
visualization and simulation techniques that enable designers to achieve new
levels of performance. Advancing the state of the art in human-computer
interaction, computer graphics and digital design technology, Autodesk
Research collaborates openly with researchers at leading universities around
the world. The bio/nano/programmable matter group withinAutodesk Research is
extending this expertise by developing software for the design and simulation
of molecular systems and living systems.

About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for
medical research and therapeutic applications. The company is working in
collaboration with pharmaceutical and academic partners to develop human
biological disease models in three dimensions that enable therapeutic drug
discovery and development. Organovo's technology can also be applied to create
surgical tissues for direct therapy. Their three-dimensional bioprinting
technology was selected as one of the "Best Inventions of 2010" by TIME
Magazine. Organovo leads the way in solving complex medical research problems
and building the future of medicine. Visit

Safe Harbor Statement
Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is defined in the
Private Securities Litigation Reform Act of 1995. Any forward-looking
statements contained herein are based on current expectations, but are subject
to a number of risks and uncertainties. The factors that could cause actual
future results to differ materially from current expectations include, but are
not limited to, risks and uncertainties relating to the Company's ability to
develop, market and sell products based on its technology; the expected
benefits and efficacy of the Company's products and technology; the
availability of substantial additional funding for the Company to continue its
operations and to conduct research and development, clinical studies and
future product commercialization; the anticipated benefits of the contract
with Autodesk; and the Company's business, research, product development,
regulatory approval, marketing and distribution plans and strategies. These
and other factors are identified and described in more detail in our filings
with the SEC, including our current report on Form 8-K/A filed on May 11,
2012. We do not undertake to update these forward-looking statements made by

SOURCE Organovo Holdings, Inc.

Contact: Investor, Barry Michaels, Chief Financial Officer, +1-858-224-1003,, or Gerry Amato, Booke & Company Investor Relations,, or Media, Mike Renard, EVP, Commercial Operations,
Press spacebar to pause and continue. Press esc to stop.